BioCryst Pharmaceuticals secured a $69 million contract with the U.S. Department of Health and Human Services to supply RAPIVAB® for influenza treatment over five years. The agreement aims to strengthen the Strategic National Stockpile for emergencies, with an initial order placed for 19,125 doses.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing